These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25476796)

  • 21. Cell therapy, 3D culture systems and tissue engineering for cardiac regeneration.
    Emmert MY; Hitchcock RW; Hoerstrup SP
    Adv Drug Deliv Rev; 2014 Apr; 69-70():254-69. PubMed ID: 24378579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imaging technologies for monitoring the safety, efficacy and mechanisms of action of cell-based regenerative medicine therapies in models of kidney disease.
    Sharkey J; Scarfe L; Santeramo I; Garcia-Finana M; Park BK; Poptani H; Wilm B; Taylor A; Murray P
    Eur J Pharmacol; 2016 Nov; 790():74-82. PubMed ID: 27375077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regenerative medicine: future impact on clinical therapies and society.
    Kargul J; Laurent GJ; Irminger-Finger I
    Int J Biochem Cell Biol; 2014 Nov; 56():1. PubMed ID: 25461768
    [No Abstract]   [Full Text] [Related]  

  • 24. Preparing regenerative therapies for clinical application: proposals for responsible translation.
    Shapiro SA; Smith CG; Arthurs JR; Master Z
    Regen Med; 2019 Feb; 14(2):77-84. PubMed ID: 30651044
    [No Abstract]   [Full Text] [Related]  

  • 25. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies?
    El Omar R; Beroud J; Stoltz JF; Menu P; Velot E; Decot V
    Tissue Eng Part B Rev; 2014 Oct; 20(5):523-44. PubMed ID: 24552279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Institutional profile. The International Society for Cellular Therapy: evolving to meet the demands of the regenerative medicine industry.
    Maziarz RT; Arthurs J; Horwitz E
    Regen Med; 2011 Mar; 6(2):163-6. PubMed ID: 21391849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uncertain Oversight of Regenerative Medicines in Japan under the ASRM.
    Lysaght T; Sugii S
    Cell Stem Cell; 2016 Apr; 18(4):438-9. PubMed ID: 27058936
    [No Abstract]   [Full Text] [Related]  

  • 29. Potency evaluation of tissue engineered and regenerative medicine products.
    Guthrie K; Bruce A; Sangha N; Rivera E; Basu J
    Trends Biotechnol; 2013 Sep; 31(9):505-14. PubMed ID: 23932143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Regulatory science research to facilitate the development of cell/tissue-processed products].
    Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal.
    Krampera M; Galipeau J; Shi Y; Tarte K; Sensebe L;
    Cytotherapy; 2013 Sep; 15(9):1054-61. PubMed ID: 23602578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Toxicity Studies for Regenerative Medicine in Japan.
    Shigeto J; Ichiki T; Nii T; Konno K; Nakanishi Y; Sugiyama D
    Clin Ther; 2018 Nov; 40(11):1813-1822. PubMed ID: 30458928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue engineering and regenerative medicine: past, present, and future.
    Salgado AJ; Oliveira JM; Martins A; Teixeira FG; Silva NA; Neves NM; Sousa N; Reis RL
    Int Rev Neurobiol; 2013; 108():1-33. PubMed ID: 24083429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The early career researcher's toolkit: translating tissue engineering, regenerative medicine and cell therapy products.
    Rafiq QA; Ortega I; Jenkins SI; Wilson SL; Patel AK; Barnes AL; Adams CF; Delcassian D; Smith D
    Regen Med; 2015 Nov; 10(8):989-1003. PubMed ID: 26628407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential benefits of cell therapy in coronary heart disease.
    Grimaldi V; Mancini FP; Casamassimi A; Al-Omran M; Zullo A; Infante T; Napoli C
    J Cardiol; 2013 Nov; 62(5):267-76. PubMed ID: 23834957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stress urinary incontinence animal models as a tool to study cell-based regenerative therapies targeting the urethral sphincter.
    Herrera-Imbroda B; Lara MF; Izeta A; Sievert KD; Hart ML
    Adv Drug Deliv Rev; 2015 Mar; 82-83():106-16. PubMed ID: 25453264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider.
    Sato Y; Bando H; Di Piazza M; Gowing G; Herberts C; Jackman S; Leoni G; Libertini S; MacLachlan T; McBlane JW; Pereira Mouriès L; Sharpe M; Shingleton W; Surmacz-Cordle B; Yamamoto K; van der Laan JW
    Cytotherapy; 2019 Nov; 21(11):1095-1111. PubMed ID: 31711733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toward the use of endometrial and menstrual blood mesenchymal stem cells for cell-based therapies.
    Ulrich D; Muralitharan R; Gargett CE
    Expert Opin Biol Ther; 2013 Oct; 13(10):1387-400. PubMed ID: 23930703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cryopreservation of whole adipose tissue for future use in regenerative medicine.
    Choudhery MS; Badowski M; Muise A; Pierce J; Harris DT
    J Surg Res; 2014 Mar; 187(1):24-35. PubMed ID: 24268882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?
    Schäfer R
    BMC Med; 2019 Mar; 17(1):53. PubMed ID: 30832655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.